June 09−11, 2023, Hamburg, Germany

European Academy of Allergy and Clinical Immunology (EAACI)

July 01−03, 2022

European Academy of Allergy and Clinical Immunology (EAACI)

European Academy of Allergy and Clinical Immunology (EAACI)

Oral icon

Remibrutinib (LOU064) treatment improves hive severity in patients with chronic spontaneous urticaria: Findings from a Phase 2b study

A. Gimenez-Arnau, K. Hayama, V. Jain, K. Sitz, K. Lheritier, I. Nikolaev, P. Walsh, S. Haemmerle, M. Maurer
Oral icon

Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from a 52-week phase 2b extension study

A. Gimenez-Arnau, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, S. Hugot, M. Wells, A. Zharkov, W. Carr
Oral icon

Remibrutinib (LOU064) treatment improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Phase 2b study results

M. Metz, A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh, I. Nikolaev, A. Giménez-Arnau, M. Maurer
Oral icon

Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the Phase 2b study

M. Maurer, A. Giménez-Arnau, V. Jain, A. Reich, CE. Ortmann, P. Walsh, S. Haemmerle
Oral icon

Efficacy, safety, and tolerability of remibrutinib (LOU064) in CSU patients: Study design of Phase 3b extension trial

M. Maurer, A. Giménez-Arnau, S. Saini, M. Lebwohl, G. Sussman, M. Hide, K. Lheritier, A. Zharkov, S. Bhat, L. Wei, ED. Martzloff, S. Haemmerle
Oral icon

Divergent Patients' and Physicians' Perceptions of Chronic Urticaria Disease Control: An Urticaria Voices Study Outcome

PA. Laires, MM. Balp, K. Weller, TA. Winders, JA. Bernstein, M. Dricu, S. Flierl, L. Christen, N. Janssens, S. Smeets
Oral icon

Prevalence and overall disease burden of chronic spontaneous urticaria in five European countries (France, Germany, Italy, Spain, and United Kingdom)

MM Balp, K Krupsky, BL Balkaran, S Gupta, C Lienhard, D Patil, RK Kohli, JM Rodriguez Barrios, A Romero, F Tétart, J Reed, T El-Shanawany
Oral icon

Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study in chronic spontaneous urticaria patients

A. M. Giménez-Arnau, M. Maurer, M. Metz, V. Jain, P. Walsh, K. Lheritier, S. Hugot, H. Zouater, S. Haemmerle, A. Zharkov
Poster icon

More patients achieve absence of angioedema with remibrutinib (LOU064) than placebo: Results from a dose-finding Phase 2b study

M. Maurer, J. Reed, P. Staubach, K. Lheritier, P. Walsh, I. Nikolaev, S. Haemmerle, A. M. Giménez-Arnau
Oral icon

Remibrutinib (LOU064) reduces the use of rescue medication in patients with chronic spontaneous urticaria: Findings from a Phase 2b study

M. Maurer, J. Reed, P. Staubach, K. Lheritier, P. Walsh, V. Meti, I. Nikolaev, S. Haemmerle, A. M. Giménez-Arnau
Poster icon

Angioedema control with ligelizumab in patients with chronic spontaneous urticaria correlates with improvement of health-related quality of life

M. Metz, A. M. Giménez-Arnau, M. Maurer, M. Hide, K. Sitz, C-E. Ortmann, M-M. Balp, T. Severin
Poster icon

Ligelizumab achieves complete response in chronic spontaneous urticaria patients with or without angioedema at baseline: A composite score evaluation

A. M. Giménez-Arnau , M. Maurer, J. A. Bernstein, G. Sussmann, M. Hide, C-E. Ortmann, T. Severin
Oral icon

Ligelizumab is effective in chronic spontaneous urticaria patients with and without serum autoreactivity assessed by basophil histamine release assay

M. Maurer, W. Soong, A. M. Giménez-Arnau, J. A. Bernstein, E. Hua, C-E. Ortmann, T. Severin
Poster icon

Long term control of urticaria disease activity with ligelizumab in patients with CSU: data from the Phase 2b extension study

J. A. Bernstein, P. Staubach, M. Maurer, S. Savic, M. Hide, T. Severin, E. Hua
Poster icon

Evaluating the implementation and effectiveness of an "Urticaria Care Package" to support the assessment and use of Patient Reported Outcomes in the management of Chronic Spontaneous Urticaria: An implementation science project

P. A. Laires, M. Bartezaghi, O. Bonavita, E. Peruzzi, G. Dasari, N. Janssens, V. Herrera, E. Gibbons, J. N. Hill, I. Nikolaev, S. De Geest
Poster icon

Low urticaria control test (UCT) scores are a significant predictor of poor response to antihistamines: analysis from worldwide real-world data (AWARE study)

A. Rajan, P. A. Laires, N. Janssens, S. Rizvi, S. Smeets, K. Weller
Poster icon

Comparative economic burden of chronic spontaneous urticaria, psoriasis and atopic dermatitis in five European countries (France, Germany, Italy, Spain, United Kingdom)

S. Gupta, M-M. Balp, S. Walsh, B. L. Balkaran, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, K. Krupsky, A. Romero, T. El-Shanawany, F. Tétart, J. Reed
Poster icon

Humanistic burden of chronic spontaneous urticaria relative to psoriasis and atopic dermatitis in five European countries (France, Germany, Italy, Spain, United Kingdom)

M-M. Balp, S. Walsh, B. L. Balkaran, S. Gupta, K. Krupsky, C. Lienhard, J. Loh, J.M. Rodriguez Barrios, A. Romero, F. Tétart, T. El-Shanawany, J. Reed
Poster icon

Impact of severity on the economic burden of chronic spontaneous urticaria in five European countries (France, Germany, Italy, Spain, United Kingdom)

M-M. Balp, K. Krupsky, B.L. Balkaran, S. Gupta, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, A. Romero, S. Walsh, J. Reed, T. El-Shanawany, F. Tétart
Poster icon

Impact of severity on the humanistic burden of chronic spontaneous urticaria in five European countries (France, Germany, Italy, Spain, United Kingdom)

S. Gupta, M-M. Balp, B. L. Balkaran, K. Krupsky, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, S. Walsh, A. Romero, F. Tétart, J. Reed, T. El-Shanawany
Poster icon

Prevalence and clinical profile of patients with chronic inducible urticaria in the EU5 (France, Germany, Italy, Spain, United Kingdom)

M-M. Balp, K. Krupsky, B. L. Balkaran, S. Gupta, C. Lienhard, S. Walsh, J. Loh, J. M. Rodriguez Barrios, A. Romero, F. Tétart, J. Reed, T. El-Shanawany
Poster icon

Comorbidity burden and healthcare resource utilization associated with non-response to H1-antihistamines alone or in combination with non-biologic treatments for chronic spontaneous urticaria

W. Soong, D. Patil, I. Pivneva, R. Bhak, J. Signorovitch, M-M. Balp, K. Freedle
Poster icon

Chronic spontaneous urticaria systems biology-based models for the mechanistic evaluation of novel targets

J. Gómez, C. Segú-Vergés, P. Terradas, L. Artigas, S. Smeets, M. Ferrer, S. Savic
Poster icon

Systems biology-based mechanistic models support the centrality of mast cell activation and the IgE- FcεRI axis in chronic spontaneous urticaria

J. Gómez, C. Segú-Vergés, P. Terradas, L. Artigas, S. Smeets, M. Ferrer, S. Savic
Poster icon

Evaluating the impact of chronic spontaneous urticaria on patients’ lives using social media listening

E. Kocatürk, M. Bizjak, E. S. Baldrich, L. Walter, P. Terradas, L. Christen, N. Janssens, S. Smeets
Poster icon

Moderate to severe chronic spontaneous urticaria has a similar quality of life impact to moderate to severe plaque psoriasis: results from the data42 platform to repurpose clinical trial data

I. Nikolaev, N. Barbier, C-E. Ortmann, N. Janssens, N. Chapman-Rothe, N. Hajizadeh, O. Hsine, A. Rajan, P. A. Laires, H. Edgren

Symposia

Chronic spontaneous urticaria: Defining the pathway to successful management

Maurer M, Kocatürk E and Savic S

Slides Video icon Symposia

Poster icon

Welcome & Introduction

M. Maurer
 
Poster icon

Chronic Spontaneous Urticaria: defining the pathway to successful management
A panel discussion on overcoming roadblocks to CSU care, based on real life experiences

M. Maurer, E. Kocatürk and S. Savic
 
Poster icon

Live Q&A

M. Maurer, E. Kocatürk and S. Savic
 

2021

Poster icon

Ligelizumab achieves fast control of symptoms in patients with chronic spontaneous urticaria: A rolling UAS7 analysis

M. Maurer, A. M. Giménez-Arnau, W. Soong, M. Hide, J. A. Bernstein, S. Acharya, A. Barve, T. Severin
Poster icon

Evaluating complete control of urticaria with ligelizumab: A composite score of symptoms and quality-of-life outcome

A. M. Giménez-Arnau, M. Maurer, J. A. Bernstein, K. Sitz, G. Sussman, S. Acharya, P. Terradas-Montana, T. Severin
Poster icon

Predicting time to natural remission in chronic urticaria using random survival forest model

I. Pivneva, M-M Balp, Y. Geissbühler, A. Danyliv, T. Severin, S. Smeets, J. Signorovitch, J. Royer, Y. Liang, T. Cornwall, J. Pan, A. Marsland, W. Soong
Poster icon

Factors influencing natural remission in chronic urticaria – preliminary results from a machine learning real-world study

M-M. Balp, I. Pivneva, Y. Geissbühler, T. Severin, S. Smeets, J. Signorovitch, J. Royer, Y. Liang, T. Cornwall, J. Pan, A. Danyliv, W. Soong, A. Marsland
Poster icon

Prevalence and incidence of diagnosed chronic inducible urticaria (CIndU) in the insured US population: A real-world study using claims data

M-M. Balp, Y. Geissbühler, A. Mcconnon, J. Schäl, J. Gomme, S. Pal, S. J. McKenna, P. A. Laires, W. Soong
Poster icon

Prevalence and incidence of diagnosed chronic spontaneous/idiopathic urticaria (CSU/CIU) in the insured US population: a real-world study using claims data

Y. Geissbühler, M-M. Balp, A. Mcconnon, J. Schäl, J. Gomme, S. Pal, S. J. McKenna, P. A. Laires, W. Soong

Symposia

The many faces of IgE-mediated disease – A symposia series
Complete control of CSU - mission (im)possible

M. Maurer and Z. Brzoza

Slides Video icon Symposia

Poster icon

Why do our patients fail to reach complete control?

Z. Brzoza
 
Poster icon

How can targeting IgE contribute to complete control?

M. Maurer
 

2020

Poster icon

Study design and rationale of a phase 3b extension study of ligelizumab in adult and adolescent patients with chronic spontaneous urticaria

T. Severin, M. Maurer, A. M. Giménez-Arnau, M. Hide, G. Sussman, S. S. Saini, E. Hua, A. Barve, Y. Joubert, I. Indermuehle, R. Janocha
Poster icon

Long-term treatment with ligelizumab achieves prolonged symptom control in chronic spontaneous urticaria patients during the post-treatment follow-up

W. Soong, M. Metz, J. A. Bernstein, G. Sussman, B. Lanier, K. Sitz, M. Maurer, A. M. Giménez-Arnau, E. Hua, A. Barve, T. Severin, R. Janocha
Poster icon

Treatment with ligelizumab achieves over forty percent higher complete response rate in chronic spontaneous urticaria patients originally treated with omalizumab

M. Maurer, A. M. Giménez-Arnau, W. Soong, J.A. Bernstein, G. Sussman, M. Metz, B. Lanier, M. Hide, K. Sitz, E. Hua, A. Barve, T. Severin, R. Janocha
Poster icon

Disease control correlates with improvement of dermatology quality of life in CSU patients with angioedema treated with ligelizumab

A. M. Giménez-Arnau, M. Maurer, W. Soong, J. A. Bernstein, G. Sussman, M. Metz, B. Lanier, M. Hide, K. Sitz, E. Hua, P. Gupta, A. Barve, T. Severin, R. Janocha, M. Balp
Poster icon

Ligelizumab achieves high rate of complete responses in patients with moderate to severe chronic spontaneous urticaria

A. J. Bernstein, M. Maurer, A. M. Giménez-Arnau, W. Soong, G. Sussman, M. Metz, B. Lanier, K. Sitz, M. Hide, E. Hua, A. Barve, T. Severin, R. Janocha

Symposia

Breakthrough in the understanding of the anti-IgE pathway in CSU

M. Maurer, A. Eggel

Video icon Symposia

Poster icon

IgE inhibition in CSU: Not all anti-IgEs are born equal

A. Eggel
Poster icon

IgE inhibition implications: How does this benefit patients with chronic spontaneous urticaria?

M. Maurer

2019

Poster icon

Ligelizumab achieves sustained control of chronic spontaneous urticaria symptoms of hives, itch and angioedema: 1-year treatment results

J.A. Bernstein, D. Baker, M. Maurer, A. Giménez -Arnau, G. Sussman, A. Barve, E. Hua, T. Severin, R. Janocha
Poster icon

LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin

M. Kaul, J. Storim, P. End, M. Cabanski, A. Jakab, C. Schuhler, E. Funhoff, F. Schaefer, E. Dimanova, M. Kistowska, A. Kinhikar, A. Maiolica, A. Sinn, R. Fuhr, B. Cenni
Poster icon

Ligelizumab is well tolerated and exhibits a safety profile similar to omalizumab and placebo in patients with chronic spontaneous urticaria

G. Sussman, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin, R. Janocha
Poster icon

Ligelizumab retreatment is highly effective in patients with chronic spontaneous urticaria

M. Maurer, A. M. Giménez-Arnau, G. Sussman, E. Hua, T. Severin, R. Janocha

2018

Poster icon

Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: Primary results of a placebo- and active-controlled, phase 2b dose-finding study

M. Maurer, A. Giménez -Arnau, G. Sussman, J. Loeffler, A. Barve, T. Severin, R. Janocha
© Copyright 2024 Novartis Pharma AG